Goldman Sachs’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Goldman Sachs’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-16,404	Closed	-$597K	–	7219
2016 Q4	$597K	Buy	+16,404	New	+$580K	﹤0.01%	4901
2015 Q4	–	Sell	-14,955	Closed	-$58K	–	7545
2015 Q3	$58K	Buy	+14,955	New	+$110K	﹤0.01%	6739

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

Goldman Sachs's CLCD Position: Q1 2017 in Review

Goldman Sachs sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 16,404 shares — an estimated $597K sold.

Goldman Sachs first reported a position in CLCD in Q3 2015 and held it in 2 quarters. The position peaked at $597K in Q4 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

Goldman Sachs reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Goldman Sachs sold 16,404 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $597K.
Goldman Sachs first reported a position in CoLucid Pharmaceuticals, Inc. in Q3 2015 and held it in 2 quarters.
Goldman Sachs's CoLucid Pharmaceuticals, Inc. position peaked at $597K in Q4 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on Goldman Sachs's 13F filing for Q1 2017, filed 15 May 2017.